EL777969461US



PTO/SB/64/PCT (10-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number (Optional)

DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b) MSB-7265-PCT-US		
First named inventor: Jianmin Chen		
International (PCT) Application No.: US01/10222 U.S. Application No.: Unknown		
Filed: 30 March 2001 (30.03.2001) (if known)		
Title: Protein Having Activity As An Angiogenesis Modulator		
Attention: PCT Legal Staff		
Box PCT Assistant Commissioner for Patents 12 MAR 2002		
Washington, D.C. 20231 Legan المصاحبة المحاطة		
The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.494(b) or (c) or 1.495(b) or (c) as applicable). The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.494(g) or 1.495(h).		
APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION .		
NOTE: A grantable petition requires the following items: (1) Petition fee (2) Proper reply (3) Terminal disclaimer with disclaimer feerequired for all international applications having an international filing date before June 8, 1995; and (4) Statement that the entire delay was unintentional.		
1. Petition fee		
☐ Small entity - fee \$(37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.		
xx Other that small entity - fee \$1280 (37 CFR 1.17(m))		
2. Proper reply		
A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s) in the form of TransmittaleLetter concerning Filing under (identify type of reply): 35U.S.C.371 and Copy of Oath and Declaration has been filed previously on x is enclosed herewith.		

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 1.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/64/PCT (10-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee		
Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.		
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$		
4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
December 7, 201	Meline a 8h	
Date	Signature	
Telephone Number: (510) 705-7901	Melissa A. Shaw, Reg. No.38,301 Typed or printed name	
	Bayer Corporation Address	
•	800 Dwight Way, P.O. Box 1986 Berkeley, California 94701	
Enclosures: Response		
Fee Payment (See attached Terminal Disclaimer Form	fee transmittal sheet)	